Efficacy and safety of imatinib in CML over 10 years.
Rüdiger Hehlmann
Research Funding - Novartis
Lida Kalmanti
No relevant relationships to disclose
Christian Dietz
No relevant relationships to disclose
Michael Lauseker
No relevant relationships to disclose
Lisa Heinrich
No relevant relationships to disclose
Ulrike Proetel
No relevant relationships to disclose
Andreas Hochhaus
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis
Research Funding - Bristol-Myers Squibb; Novartis
Martin C. Müller
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis
Research Funding - Bristol-Myers Squibb; Novartis
Alice Fabarius
No relevant relationships to disclose
Stefan W. Krause
Honoraria - Novartis
Research Funding - Novartis
Jolanta Dengler
Honoraria - Novartis
Christiane Falge
No relevant relationships to disclose
Gabriela M. Baerlocher
No relevant relationships to disclose
Lothar Kanz
No relevant relationships to disclose
Frank Stegelmann
No relevant relationships to disclose
Michael Pfreundschuh
No relevant relationships to disclose
Karsten Spiekermann
No relevant relationships to disclose
Markus Pfirrmann
Consultant or Advisory Role - Novartis
Honoraria - Bristol-Myers Squibb
Susanne Saussele
No relevant relationships to disclose
Joerg Hasford
No relevant relationships to disclose